Imperial College London
Portrait Picture

Simon Erridge

Faculty of Medicine, Department of Surgery & Cancer

Research Postgraduate
 
 
 
//

Contact

 

simon.erridge12

 
 
//

Location

 

Block B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Nimalan:2022:10.1186/s42238-021-00114-9,
author = {Nimalan, D and Kawka, M and Erridge, S and Ergisi, M and Harris, M and Salazar, O and Ali, R and Loupasaki, K and Holvey, C and Coomber, R and Platt, M and Rucker, JJ and Khan, S and Sodergren, MH},
doi = {10.1186/s42238-021-00114-9},
journal = {Journal of Cannabis Research},
title = {UK Medical Cannabis Registry palliative care patients cohort: initial experience and outcomes},
url = {http://dx.doi.org/10.1186/s42238-021-00114-9},
volume = {4},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - IntroductionPalliative care aims to improve quality of life through optimal symptom control and pain management. Cannabis-based medicinal products (CBMPs) have a proven role in the treatment of chemotherapy-induced nausea and vomiting. However, there is a paucity of high-quality evidence with regards to the optimal therapeutic regimen, safety, and effectiveness of CBMPs in palliative care, as existing clinical trials are limited by methodological heterogeneity. The aim of this study is to summarise the outcomes of the initial subgroup of patients from the UK Medical Cannabis Registry who were prescribed CBMPs for a primary indication of palliative care, cancer pain and chemotherapy-induced nausea and vomiting, including effects on health-related quality of life and clinical safety.MethodsA case series from the UK Medical Cannabis Registry of patients, who were receiving CBMPs for the indication of palliative care was undertaken. The primary outcome consisted of changes in patient-reported outcome measures including EQ-5D-5L, General Anxiety Disorder-7 (GAD-7), Single-Item Sleep Quality Scale (SQS), Pain Visual Analog Scale (VAS) and the Australia-Modified Karnofsky Performance Scale at 1 and 3 months compared to baseline. Secondary outcomes included the incidence and characteristics of adverse events. Statistical significance was defined by p-value< 0.050.ResultsSixteen patients were included in the analysis, with a mean age of 63.25 years. Patients were predominantly prescribed CBMPs for cancer-related palliative care (n = 15, 94%). The median initial CBD and THC daily doses were 32.0 mg (Range: 20.0–384.0 mg) and 1.3 mg (Range: 1.0–16.0 mg) respectively. Improvements in patient reported health outcomes were observed according to SQS, EQ-5D-5L mobility, pain and discomfort, and anxiety and depression subdomains, EQ-5D-5L index, EQ-VAS and Pain VAS validated scales at both 1-month and 3-mo
AU  - Nimalan,D
AU  - Kawka,M
AU  - Erridge,S
AU  - Ergisi,M
AU  - Harris,M
AU  - Salazar,O
AU  - Ali,R
AU  - Loupasaki,K
AU  - Holvey,C
AU  - Coomber,R
AU  - Platt,M
AU  - Rucker,JJ
AU  - Khan,S
AU  - Sodergren,MH
DO  - 10.1186/s42238-021-00114-9
PY  - 2022///
SN  - 2522-5782
TI  - UK Medical Cannabis Registry palliative care patients cohort: initial experience and outcomes
T2  - Journal of Cannabis Research
UR  - http://dx.doi.org/10.1186/s42238-021-00114-9
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000737922900002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://jcannabisresearch.biomedcentral.com/articles/10.1186/s42238-021-00114-9
UR  - http://hdl.handle.net/10044/1/96908
VL  - 4
ER  -
Download